Nanobiotix (NASDAQ:NBTX) Sees Large Volume Increase – Here’s What Happened

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw an uptick in trading volume on Wednesday. 90,160 shares changed hands during mid-day trading, an increase of 1% from the previous session’s volume of 88,938 shares. The stock last traded at $32.0210 and had previously closed at $31.50.

Analyst Upgrades and Downgrades

NBTX has been the subject of a number of recent analyst reports. Leerink Partners lifted their price target on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research note on Thursday, June 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Friday, July 17th. Finally, Guggenheim began coverage on shares of Nanobiotix in a research note on Tuesday, September 15th. They issued a “buy” rating and a $64.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Nanobiotix has a consensus rating of “Moderate Buy” and an average target price of $46.67.

Nanobiotix Stock Up 0.6%

The company’s 50 day moving average is $38.51 and its 200 day moving average is $37.29.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.